192 related articles for article (PubMed ID: 20074734)
1. Circulating soluble receptor for advanced glycation end-product levels are decreased in patients with calcific aortic valve stenosis.
Basta G; Corciu AI; Vianello A; Del Turco S; Foffa I; Navarra T; Chiappino D; Berti S; Mazzone A
Atherosclerosis; 2010 Jun; 210(2):614-8. PubMed ID: 20074734
[TBL] [Abstract][Full Text] [Related]
2. Decreased levels of soluble receptor for advanced glycation end-products in aortic valve calcification patients.
Zheng H; Li Y; Xie N; Huang JL; Xu HF; Luo M
Genet Mol Res; 2015 Apr; 14(2):3775-83. PubMed ID: 25966147
[TBL] [Abstract][Full Text] [Related]
3. Plasma levels of soluble receptor for advanced glycation end products (sRAGE) and proinflammatory ligand for RAGE (EN-RAGE) are associated with carotid atherosclerosis in patients with peritoneal dialysis.
Kim JK; Park S; Lee MJ; Song YR; Han SH; Kim SG; Kang SW; Choi KH; Kim HJ; Yoo TH
Atherosclerosis; 2012 Jan; 220(1):208-14. PubMed ID: 21906738
[TBL] [Abstract][Full Text] [Related]
4. Pathological Role of Receptor for Advanced Glycation End Products in Calcified Aortic Valve Stenosis.
Saku K; Tahara N; Takaseya T; Otsuka H; Takagi K; Shojima T; Shintani Y; Zaima Y; Kikusaki S; Fukuda T; Oryoji A; Nishino Y; Matsui T; Kakuma T; Akiba J; Fukumoto Y; Yamagishi SI; Tanaka H
J Am Heart Assoc; 2020 Jul; 9(13):e015261. PubMed ID: 32552251
[TBL] [Abstract][Full Text] [Related]
5. Understanding the structural features of symptomatic calcific aortic valve stenosis: A broad-spectrum clinico-pathologic study in 236 consecutive surgical cases.
Galli D; Manuguerra R; Monaco R; Manotti L; Goldoni M; Becchi G; Carubbi C; Vignali G; Cucurachi N; Gherli T; Nicolini F; Lorusso R; Vitale M; Corradi D
Int J Cardiol; 2017 Feb; 228():364-374. PubMed ID: 27866029
[TBL] [Abstract][Full Text] [Related]
6. Lipoprotein-associated phospholipase A2 is elevated in patients with severe aortic valve stenosis without clinically overt atherosclerosis.
Kolasa-Trela R; Fil K; Bazanek M; Grudzień G; Sobczyk D; Sadowski J; Undas A
Clin Chem Lab Med; 2012 Oct; 50(10):1825-31. PubMed ID: 23089713
[TBL] [Abstract][Full Text] [Related]
7. C-reactive protein in predicting coronary artery disease in subjects with aortic valve sclerosis before diagnostic coronary angiography.
Hsu SY; Hung KC; Chang SH; Wen MS; Hsieh IC
Am J Med Sci; 2006 May; 331(5):264-9. PubMed ID: 16702796
[TBL] [Abstract][Full Text] [Related]
8. Comparison of Lipoprotein(a)-Levels in Patients ≥70 Years of Age With Versus Without Aortic Valve Stenosis.
Mahabadi AA; Kahlert P; Kahlert HA; Dykun I; Balcer B; Forsting M; Heusch G; Rassaf T
Am J Cardiol; 2018 Aug; 122(4):645-649. PubMed ID: 29954600
[TBL] [Abstract][Full Text] [Related]
9. Correlation of high sensitivity C-reactive protein and calcific aortic valve disease.
Jeevanantham V; Singh N; Izuora K; D'Souza JP; Hsi DH
Mayo Clin Proc; 2007 Feb; 82(2):171-4. PubMed ID: 17290723
[TBL] [Abstract][Full Text] [Related]
10. Accumulation of advanced glycation end products (AGEs) is associated with the severity of aortic stenosis in patients with concomitant type 2 diabetes.
Kopytek M; Ząbczyk M; Mazur P; Undas A; Natorska J
Cardiovasc Diabetol; 2020 Jun; 19(1):92. PubMed ID: 32552684
[TBL] [Abstract][Full Text] [Related]
11. Can serum lipid and CRP levels predict the "severity" of aortic valve stenosis?
Gunduz H; Akdemir R; Binak E; Tamer A; Keser N; Uyan C
Acta Cardiol; 2003 Aug; 58(4):321-6. PubMed ID: 12948037
[TBL] [Abstract][Full Text] [Related]
12. One-year observation of inflammatory markers in patients with aortic valve stenosis.
Swierszcz J; Dubiel JS; Krzysiek J; Sztefko K
J Heart Valve Dis; 2011 Nov; 20(6):639-49. PubMed ID: 22655494
[TBL] [Abstract][Full Text] [Related]
13. Association between pentraxin 3 levels and aortic valve calcification.
Norimatsu K; Miura S; Suematsu Y; Shiga Y; Miyase Y; Nakamura A; Zhang B; Saku K
J Cardiol; 2016 Jul; 68(1):76-82. PubMed ID: 26388550
[TBL] [Abstract][Full Text] [Related]
14. Effect of statin treatment on aortic valve and coronary artery calcification.
Mohler ER; Wang H; Medenilla E; Scott C
J Heart Valve Dis; 2007 Jul; 16(4):378-86. PubMed ID: 17702362
[TBL] [Abstract][Full Text] [Related]
15. Local and systemic RAGE axis changes in pulmonary hypertension: CTEPH and iPAH.
Moser B; Megerle A; Bekos C; Janik S; Szerafin T; Birner P; Schiefer AI; Mildner M; Lang I; Skoro-Sajer N; Sadushi-Kolici R; Taghavi S; Klepetko W; Ankersmit HJ
PLoS One; 2014; 9(9):e106440. PubMed ID: 25188497
[TBL] [Abstract][Full Text] [Related]
16. Clinical factors, but not C-reactive protein, predict progression of calcific aortic-valve disease: the Cardiovascular Health Study.
Novaro GM; Katz R; Aviles RJ; Gottdiener JS; Cushman M; Psaty BM; Otto CM; Griffin BP
J Am Coll Cardiol; 2007 Nov; 50(20):1992-8. PubMed ID: 17996566
[TBL] [Abstract][Full Text] [Related]
17. Association between circulating oxidised low-density lipoprotein and fibrocalcific remodelling of the aortic valve in aortic stenosis.
Côté C; Pibarot P; Després JP; Mohty D; Cartier A; Arsenault BJ; Couture C; Mathieu P
Heart; 2008 Sep; 94(9):1175-80. PubMed ID: 17932090
[TBL] [Abstract][Full Text] [Related]
18. Evaluation of links between high-density lipoprotein genetics, functionality, and aortic valve stenosis risk in humans.
Arsenault BJ; Dubé MP; Brodeur MR; de Oliveira Moraes AB; Lavoie V; Kernaleguen AE; Guauque-Olarte S; Mathieu P; Pibarot P; Messika-Zeitoun D; Bossé Y; Rhainds D; Rhéaume E; Tardif JC
Arterioscler Thromb Vasc Biol; 2014 Feb; 34(2):457-62. PubMed ID: 24334872
[TBL] [Abstract][Full Text] [Related]
19. Reduced soluble receptor for advanced glycation end-products in COPD.
Smith DJ; Yerkovich ST; Towers MA; Carroll ML; Thomas R; Upham JW
Eur Respir J; 2011 Mar; 37(3):516-22. PubMed ID: 20595148
[TBL] [Abstract][Full Text] [Related]
20. The Contribution of Whole Blood Viscosity to the Process of Aortic Valve Sclerosis.
Sercelik A; Besnili AF
Med Princ Pract; 2018; 27(2):173-178. PubMed ID: 29421801
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
